DURHAM, N.C., Feb. 2 /PRNewswire/ -- Cancer Advances, Inc. (Cancer Advances), a Cato BioVentures portfolio company, announced today that it has completed its acquisition of all the technology and intellectual property for a suite of products that enhance the immune system for application in three gastrointestinal cancers. Cancer Advances was created as a wholly owned subsidiary of Cato BioVentures to acquire products developed to inhibit the hormone, gastrin, for an undisclosed purchase price. This broad intellectual property portfolio includes composition and use-protection for a lead compound, Polyclonal Antibody Stimulator (PAS), that has been clinically studied in gastric, pancreatic, and colorectal cancers. Cato Research Ltd. (Cato Research) will be responsible for Cancer Advances' strategic drug development and regulatory activities.
"We are excited about continuing the development of PAS in pancreatic and gastric cancers," said Lynda Sutton, COO of Cato Research and President of Cancer Advances. "The flexible, broad-based strategic relationship between Cancer Advances, Cato BioVentures, and Cato Research position us well to execute our innovative drug development model where we are able to fully leverage our contract research and development resources while remaining capital efficient."
The purchase agreement includes multiple patents as well as clinical and safety data for the more than 1,100 patients who have been treated with PAS to date for gastric, pancreatic, and colorectal cancers. Cancer Advances will be seeking additional funding for the company as well as potential development partners.
PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal
|SOURCE Cancer Advances, Inc.|
Copyright©2009 PR Newswire.
All rights reserved